Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–14. https://doi.org/10.1007/s10549-013-2711-y.

Article  PubMed  Google Scholar 

Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. https://doi.org/10.1016/j.annonc.2020.09.010.

Article  PubMed  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39. https://doi.org/10.1016/s1470-2045(15)00613-0.

Article  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. https://doi.org/10.1056/NEJMoa1609709.

Article  PubMed  Google Scholar 

Torres-Guzmán R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget. 2017;8(41):69493–507. https://doi.org/10.18632/oncotarget.17778.

Article  PubMed  PubMed Central  Google Scholar 

Lallena MJ, Boehnke K, Torres R, et al. Abstract 3101: in-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines. Cancer Res. 2015;75(15):3101–3101. https://doi.org/10.1158/1538-7445.Am2015-3101.

Article  Google Scholar 

Torres-Guzmán R, Ganado MP, Mur C, et al. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation. Oncotarget. 2022;13:864–75. https://doi.org/10.18632/oncotarget.28249.

Article  PubMed  PubMed Central  Google Scholar 

Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–24. https://doi.org/10.1158/1078-0432.Ccr-17-0754.

Article  PubMed  PubMed Central  Google Scholar 

Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84. https://doi.org/10.1200/jco.2017.73.7585.

Article  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46. https://doi.org/10.1200/jco.2017.75.6155.

Article  PubMed  Google Scholar 

Toi M, Inoue K, Masuda N, et al. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci. 2021;112(6):2381–92. https://doi.org/10.1111/cas.14877.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Noma S, Taguchi Y, et al. Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan. Breast Cancer. 2021;28(3):710–9. https://doi.org/10.1007/s12282-020-01207-8.

Article  PubMed  Google Scholar 

Inoue K, Masuda N, Iwata H, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28(5):1038–50. https://doi.org/10.1007/s12282-021-01239-8.

Article  PubMed  Google Scholar 

Takahashi M, Tokunaga E, Mori J, et al. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer. 2022;29(1):174–84. https://doi.org/10.1007/s12282-021-01295-0.

Article  PubMed  Google Scholar 

Samuelsen SO. A psudolikelihood approach to analysis of nested case-control studies. Biometrika. 1997;84(2):379–94. https://doi.org/10.1093/biomet/84.2.379.

Article  Google Scholar 

Scagnoli S, Pisegna S, Toss A, et al. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ Breast Cancer. 2024;10(1):58. https://doi.org/10.1038/s41523-024-00657-z.

Article  PubMed  PubMed Central  Google Scholar 

Lin W, Zeng Y, Weng L, Yang J, Zhuang W. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study. BMC Pharmacol Toxicol. 2024;25(1):47. https://doi.org/10.1186/s40360-024-00770-6.

Article  PubMed  PubMed Central  Google Scholar 

Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12. https://doi.org/10.1056/NEJMoa1013660.

Article  PubMed  PubMed Central  Google Scholar 

Swigris JJ, Olson AL, Huie TJ, et al. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med. 2012;106(4):588–93. https://doi.org/10.1016/j.rmed.2012.01.002.

Article  PubMed  PubMed Central  Google Scholar 

Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260–77. https://doi.org/10.1016/j.resinv.2013.09.001.

Article  PubMed  Google Scholar 

Iwasa E, Fujiyoshi Y, Kubota Y, et al. Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting. Drug Saf. 2020;43(11):1121–31. https://doi.org/10.1007/s40264-020-00968-7.

Article  PubMed  PubMed Central  Google Scholar 

Ushiki A, Hanaoka M. Clinical characteristics of DLI: what are the clinical features of DLI? In: Hanaoka M, Nakamura H, Aoshiba K, editors. Drug-induced lung injury. Springer: Singapore; 2018. p. 27–33.

Chapter  Google Scholar 

Komada F, Nakayama Y, Takara K. Analysis of time-to-onset and onset-pattern of interstitial lung disease after the administration of monoclonal antibody agents. Yakugaku Zasshi. 2018;138(12):1587–94. https://doi.org/10.1248/yakushi.18-00094.

Article  PubMed  Google Scholar 

Matsumoto K, Nakao S, Hasegawa S, et al. Analysis of drug-induced interstitial lung disease using the Japanese adverse drug event report database. SAGE Open Med. 2020;8:2050312120918264. https://doi.org/10.1177/2050312120918264.

Article  PubMed  PubMed Central  Google Scholar 

Osawa M, Kudoh S, Sakai F, et al. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol. 2015;20(6):1063–71. https://doi.org/10.1007/s10147-015-0834-3.

Article  PubMed  PubMed Central  Google Scholar 

Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. https://doi.org/10.1016/j.esmoop.2022.100404.

Article  PubMed  PubMed Central  Google Scholar 

Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol. 2017;47(9):832–9. https://doi.org/10.1093/jjco/hyx075.

Article  PubMed  PubMed Central  Google Scholar 

Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98. https://doi.org/10.1200/jco.20.02514.

Article  PubMed  PubMed Central  Google Scholar 

Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci. 2014;105(12):1584–90. https://doi.org/10.1111/cas.12550.

Article  PubMed  PubMed Central  Google Scholar 

Nakano K, Seto A, Sasaki T, et al. Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab. Head Neck. 2019;41(8):2574–80.